Ann Arbor, Michigan, September 13, 2006 -- Aastrom Biosciences, Inc. (Nasdaq: ASTM) today reported financial results for the fourth quarter and fiscal year ended June 30, 2006. The Company also reported several clinical and operational achievements during the quarter, including: Completion of the

Webcast Alert: Aastrom Biosciences Announces Its Fourth Quarter Investor Conference Call Ann Arbor, MI, September 6, 2006 -- Aastrom Biosciences, Inc. (NASDAQ: ASTM) announces the following Webcast: What: Aastrom Biosciences, Inc. Fourth Quarter Fiscal Year End 2006 Investor Conference Call When:

AASTROM BIOSCIENCES APPOINTS SENIOR DIRECTORMEDICAL AFFAIRS

GEORGE W. DUNBAR JOINS AASTROM BIOSCIENCESAS CHIEF EXECUTIVE OFFICER

AASTROM BIOSCIENCES ACHIEVES U.S. BONE FRACTURECLINICAL MILESTONE

AASTROM BIOSCIENCES' CEO TO PRESENT AT RODMAN & RENSHAW 3rd ANNUAL GLOBAL HEALTHCARE CONFERENCE

AASTROM BIOSCIENCES, INC. REPORTS THIRD QUARTERFISCAL YEAR 2006 FINANCIAL RESULTS

AASTROM BIOSCIENCES' RECEIVES MANUFACTURING LICENSEAT EUROPEAN PILOT FACILITY FOR PRODUCTION OFPROPRIETARY BONE MARROW STEM CELL PRODUCTS

Webcast Alert: Aastrom Biosciences Announces ItsThird Quarter Investor Conference Call

Aastrom Biosciences to Raise $25.5 Million in Equity Financing Ann Arbor, Michigan, April 6, 2006 – Aastrom Biosciences, Inc. (Nasdaq: ASTM) announced today that it has executed definitive Purchase Agreements for the sale of approximately 15.9 million shares of the Company's common stock in a